Navigation Links
Kalorama: With Alzheimer's Disease, A Quest to Know More Fuels Biomarker Search

NEW YORK, Dec. 3, 2015 /PRNewswire/ -- The quest to diagnose and to affect the progress of Alzheimer's relies on better research, according to Kalorama Information. For Alzheimer's to be solved, knowledge about the disease must be improved, and that means biomarker search efforts should persist near-term, according to the healthcare market research firm. Nervous system or neurological biomarkers are covered in the Kalorama Information's report Proteomics Research Markets

"An incomplete understanding of the causes behind the diseases from a systems biology standpoint has also stalled clinical diagnostics development, even when CNS samples such as cerebrospinal fluid (CSF) are available," said Kalorama Information analyst Emil Salazar in a recent blog post.

The debilitating neurodegenerative diseases Alzheimer's and Parkinson's have vexed healthcare in terms of both therapy and definitive antemortem diagnosis. The localized nature of the diseases in the central nervous system (CNS) makes the development of in vitro diagnostic (IVD) tests difficult. The incentive to develop marketable clinical assays has also been diminished to an extent by a lack of curative therapies for neurodegenerative diseases; clinicians are less apt to request or use a lab test to direct decision making for a disease without curative therapies. Still, clinical value exists for diagnostics able to detect pre-symptomatic onset of Alzheimer's and Parkinson's and inform earlier implementation of palliative care and neuroprotective therapy. Kalorama Information said nervous system biomarkers are the second-fastest growing segment in the clinical and research biomarkers markets. Researchers have heavily targeted Alzheimer's Disease (AD) diagnostics development using CSF samples and even skin samples. 

 Kalorama notes a few examples of efforts underway:

  • One study in Mexico took skin biopsies from patients with Alzheimer's, Parkinson's and non-Alzheimer's dementia as well as similarly aged healthy patients and used immunohistochemistry (IHC) tests to assay levels of tau protein. The biomarker was found to be significantly elevated in the skin samples of Alzheimer's and Parkinson's patients; alpha-synuclein protein was also found to be elevated in the samples of Parkinson's patients. Skin samples are theorized to be feasible proxies for brain tissue because of the samples' common origin in embryonic development.
  • Another study identified protein kinase C epsilon (PKCe) as a biomarker for AD with reduced levels observed in AD patient skin samples. Development-stage therapeutics company Neurotrope is interested in a PKCe modulator as a potential treatment for AD patients. While CSF biomarker tests for AD are further along in development, skin biopsy tests would be much more widely implementable in healthcare.
  • Amarantus Bioscience offers a blood-based assay as a non-invasive alternative to CSF-based AD tests. The Lymphocyte Proliferation (LymPro) assay is able to differentiate AD individuals from other forms of dementia and healthy individuals by measuring the expression of CD69 protein during stimulated lymphocyte mitosis or cell division. In AD individuals, CD69 expression is down regulated compared to healthy individuals and those with other forms of dementia. The lymphocyte cell surface CD69 markers are measured using flow cytometry. In the test, peripheral blood lymphocytes are used as surrogates for neurons that theoretically exhibit the same cell cycle dysfunction. 
  • Researchers at Merck have seized upon MS to meet evolving protein analysis demands, selecting immunoaffinity microflow LC-triple quad MS to identify different isoforms of tau biomarkers arising from post-translational modification. Immunoassays do not provide the specificity necessary to identify tau modifications that potentially influence disease progression.
  • Thermo Fisher has applied its own immunoenrichment triple quad MS approach for low-abundance blood proteins to the discovery and monitoring of AD biomarkers. Researchers have used Thermo's multiplexed mass spectrometric immunoassay (MSIA)-SRM assays for the quantitation of aberrant ceruloplasmin (affects homeostasis of free copper and results in AD-associated protein degradation and aggregation) and apolipoprotein E (promotes AD-associated beta amyloid fibril formation).

Kalorama's report, Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) contains breakouts of the market by type of technology used and application. It profiles companies and surveys partnerships and deals related to proteomics. Find this report in addition to other industry leading research from Kalorama at:

About Kalorama Information

Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on and

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at  

Bruce Carlson
(212) 807-2622

Logo -


SOURCE Kalorama Information
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Kalorama: Molecular Diagnostics Market Reaches 6.1 Billion Dollars
2. Kalorama: Surprisingly, Beer and Biopharmaceuticals Adopt a Similar Approach
3. Kalorama: Clinical Laboratory Services Market Reaches $102 Billion
4. Kalorama: A 5.4 Billion-Dollar Business in Automating Clinical Laboratories
5. Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firms IVD Future
6. Kalorama: PCR The Go-to Test in Ebola Fight
7. Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production
8. Kalorama: Yellen Comments on Biotechnology Sector At Odds With Venture Capital Trends
9. Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting
10. StromAb, First-In-Class Antibody Dissolves Thrombus In ACUTE Stroke & Cardiovascular Disease, In Production Phase I Clinical Trials
11. Quest PharmaTechs Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer
Post Your Comments:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):